CN101797330B - Lipid regulating and meridians activating capsule - Google Patents
Lipid regulating and meridians activating capsule Download PDFInfo
- Publication number
- CN101797330B CN101797330B CN2010101424243A CN201010142424A CN101797330B CN 101797330 B CN101797330 B CN 101797330B CN 2010101424243 A CN2010101424243 A CN 2010101424243A CN 201010142424 A CN201010142424 A CN 201010142424A CN 101797330 B CN101797330 B CN 101797330B
- Authority
- CN
- China
- Prior art keywords
- meridians
- spina gleditsiae
- sanguis draxonis
- ginseng rubra
- radix notoginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a lipid regulating and meridians activating capsule prepared from the following raw materials in percentage by weight: 25%-30% of red ginseng, 35%-42% of red kojic, 24%-27% of spina gleditsiae, 4%-6% of pseudo-ginseng and 2%-3% of dragon blood. The invention not only considers various pathogenic factors of coronary heart disease, but also pays attention to the rise and fall of qi and blood and the yin and yang of a whole body, not only emphasizes local patholoic change of coronary arteries (heart vessels and meridians), but also pays more attention to the integral relation of the coronary arteries and the whole body, achieves the integral regulation aiming at a plurality of pathological links and multiple levels and target spots and dialectically treats the coronary heart disease and hyperlipaemia and has superior effect especially for patients with long disease courses and more obstinate disease conditions.
Description
Technical field
The present invention relates to Chinese medicine composition, especially relate to the lipid regulating and meridians activating capsule that integrates control angina pectoris and hyperlipemia.
Background technology
Coronary heart disease is one of serious disease that threatens human health, and since nearly half a century, crowd's coronary heart disease prevalence and mortality rate constantly rise, and have become human mortality's first cause.According to statistics, China's coronary heart disease human mortality is about 3/10000ths, still has the trend of rising at present.And cause of coronary heart disease often occurs in ability to work with death and creative ability is the highest, society and family are contributed maximum age group, has caused very big harm for the mankind and society.
The Drug therapy of coronary heart disease has Western medicine and Chinese medicine at present.Western medicine has nitrate esters, beta-blocker, calcium antagonist etc., and dosage form has tablet, injection, pad pasting, though there is side effect in various degree in determined curative effect, particularly widely applies for a long time, and bigger untoward reaction is arranged.The Chinese medicine method of treatment has blood circulation promoting and blood stasis dispelling, benefiting QI for activating blood circulation, vital energy benefiting and the kidney invigorating, aromatic herbs activating YANG and eleminating phlegm and freeing channels, and how Chinese patent medicine is method of treatment from blood circulation promoting and blood stasis dispelling, benefiting QI for activating blood circulation relatively.Along with growth in the living standard, the conversion of dietary habit makes the tcm syndrome spectrum of coronary heart disease that significant change take place, so tcm treatment method needs to variation deeply.In addition, concerning human body, the harm of hyperlipemia is very big.Blood fat is too high to be the most dangerous (easily suffering from) factor of quickening in a plurality of factors of atherosclerosis.The harm of hyperlipemia be concealment, gradually, carrying out property and general.Hyperlipemia is most important also to be that directly infringement is to quicken systemic atherosclerosis, because the vitals of whole body all will rely on tremulous pulse blood supply, oxygen supply, in case tremulous pulse is stopped up by atheromatous plaque, will cause serious consequence.Hyperlipemia is the risk factor of coronary heart disease, myocardial infarction, cardiac sudden death etc.A large amount of epidemiologic datas and extensive perspective clinical research confirmation blood plasma cholesterol level with take place between the coronary heart disease risk linear relevant, i.e. the every rising 1% of cholesterol, coronary heart disease risk rising 2%.Blood fat is not up to standard as control, and angina pectoris can not be effectively controlled.But still lack at present and prevent and treat the Chinese and western drugs of coronary heart disease and hyperlipemia simultaneously.
Summary of the invention
The object of the invention is to provide a kind of nontoxic, lipid regulating and meridians activating capsule of integrating control angina pectoris and hyperlipemia evident in efficacy, easy to use, safe.
For achieving the above object, the present invention can take following technical proposals:
Lipid regulating and meridians activating capsule of the present invention is formulated according to following weight percentage ratio by crude drug Radix Ginseng Rubra, Radix Notoginseng, Sanguis Draxonis, Monas cuspurpureus Went, Spina Gleditsiae:
Radix Ginseng Rubra: 25-30%; Monas cuspurpureus Went: 35-42%; Spina Gleditsiae: 24-27%; Radix Notoginseng: 4-6%; Sanguis Draxonis: 2-3%;
The preparation method of medicine of the present invention is:
The first step, with above-mentioned Radix Ginseng Rubra, Monas cuspurpureus Went, Spina Gleditsiae alcohol reflux, reclaim behind the ethanol gained alcohol extract to such an extent that extractum is standby;
Second step, above-mentioned Radix Notoginseng, Sanguis Draxonis are beaten powder cross 100 mesh sieves, standby;
The 3rd step, with first step gained extractum, second step gained Radix Notoginseng, the former powder of Sanguis Draxonis mixes the back boiling granulating, incapsulates to get final product.
The proportioning of described crude drug can be Radix Ginseng Rubra: 25%; Monas cuspurpureus Went: 42%; Spina Gleditsiae: 27%; Radix Notoginseng: 4%; Sanguis Draxonis: 2%.
The proportioning of described crude drug can also be Radix Ginseng Rubra: 30%; Monas cuspurpureus Went: 35%; Spina Gleditsiae: 26%; Radix Notoginseng: 6%; Sanguis Draxonis: 3%.
The proportioning of described crude drug also can be Radix Ginseng Rubra: 27%; Monas cuspurpureus Went: 40.9%; Spina Gleditsiae: 24%; Radix Notoginseng: 5.4%; Sanguis Draxonis: 2.7%.
The above-mentioned concentration of alcohol that is used for extraction is 60%; Be to guarantee finished product granularity unanimity, cross 40 mesh sieves after with its boiling granulating to reinstall capsule.
The instructions of taking of pharmaceutical preparation of the present invention is: when every capsules dose is 0.45 gram, and each 2-4 grain, day clothes 3 times.
The invention has the advantages that the various paathogenic factors of not only considering coronary heart disease, also note the prosperity and decline of whole body negative and positive of qi and blood, not only emphasize the local patholoic change of arteria coronaria (heart arteries and veins heart network), more paying attention to the globality of itself and whole body gets in touch, reach at a plurality of pathology links, at many levels, many target spots integrally-regulated, determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs coronary heart disease hyperlipemia, patient especially long for the course of disease, that the state of an illness is comparatively obstinate relatively more has superiority.The present invention adds dispelling pathogenic wind and eliminating phlegm, changes the Spina Gleditsiae, the Monas cuspurpureus Went that stagnate in transferring on the basis of benefiting QI for activating blood circulation, eleminating phlegm and freeing channels, substantial difference is arranged on method of treatment.On therapeutic effect and therapeutic domain, have breakthrough.
Because coronary heart disease belongs to the traditional Chinese medical science " thoracic obstruction " " precordial pain with cold limbs " disease categories such as " angina pectoriss ", the primary disease pathogenesis is " deficiency in origin and excess in superficiality ", and it is empty that " deficiency in origin " refers to that negative and positive of qi and blood loses, and " mark is real " has that the stagnation of QI, blood stasis, expectorant are turbid, the difference of cold coagulation.Wherein, expectorant turbid with blood stasis be the important pathological product be again paathogenic factor, expectorant comes from Tianjin, the stasis of blood is formed in blood, and the dependency on the blood physiology of Tianjin has determined that expectorant is turbid, the homology between the blood stasis and interrelated, after the expectorant stasis of blood forms, not only can cause a disease separately, also can cause the stasis of blood, cause expectorant because of the stasis of blood because of expectorant.Hyperlipemia should belong to phlegm-turbidity and blood stasis blood category, and morbidity relates to the multiple factor in inside and outside.If have a liking for food delicious food savoury, or the deficient dysfunction of the spleen in transportation that causes of taste, lifting mistake department make indigestion precise and tiny, and it is turbid to belong to expectorant, fails in blood vessels, becomes in " turbid fat ", and turbid fat is too much, and sering is unfavorable, and QI-blood circulation is obstructed, then the expectorant stasis of blood and living.Set upright simultaneously in QI invigorating, dispel that expectorant is turbid, blood stasis is important method of treatment.Control blood and need control wind, wind is walked blood voluntarily, and for the complicated disease of coronary heart disease, wind, gas, blood are taken into account simultaneously and can be cured.The present invention is a principal agent with Radix Ginseng Rubra, Radix Notoginseng, Radix Ginseng Rubra strongly invigorating primordial QI, nourishing qi to stop, and Radix Notoginseng is apt to blood stasis dispelling blood, coronary circulation-promoting pain-relieving.Be aided with the analgesic therapy of Sanguis Draxonis dissipating blood stasis, Monas cuspurpureus Went is invigorated blood circulation and is sought, helps digestion to remove and stagnates, pursues in the expectorant accent.The Spina Gleditsiae dispelling pathogenic wind and eliminating phlegm is invigorated blood circulation and to draw all medicines up, for assistant makes.All medicines share, and play benefiting QI for activating blood circulation, dispelling pathogenic wind and eliminating phlegm altogether, help digestion and remove stagnant effect.Thereby performance treatment coronary heart disease effect.
Radix Ginseng Rubra contains more than 30 kind of ginsenoside R, ginseng polysaccharide, Panacene and vitamin etc.; Mainly contain lovastatin in the Monas cuspurpureus Went, the biological active substances that ergosterol, biological flavone, saponin, dietary fiber, aminopolysaccharide etc. are abundant; Mainly contain compositions such as saccharide, Saponin, flavone, phenolic compound, protein, polypeptide, organic acid, lignanoid, steroid, triterpene, volatile oil and alkaloid in the Spina Gleditsiae.Radix Ginseng Rubra can be regulated nerve, cardiovascular and hormonal system, promotes synthesizing of body substance metabolism and protein and RNA, DNA.Radix Notoginseng has obvious blood vessel dilating, lowers coronary resistance, increases coronary flow, tightens and improves the arteria coronaria microcirculation, having additional nutrients property myocardial flow, reduce the effects such as oxygen consumption of cardiac muscle, and Spina Gleditsiae has effects such as antiinflammatory, immunomodulating, anticoagulant, blood fat reducing.Sanguis Draxonis can make blood flow unobstructed, prevents thrombosis, suppresses hematoblastic gathering, the thromboembolism preventing effect.Five kinds of Mo Na Kelin compositions in the Monas cuspurpureus Went, these five kinds of Mo Na Kelin compositions all have the synthetic effect of the cholesterol of inhibition.
The present invention is by the effect of many target spots, and clinical observation can be treated angina pectoris and hyperlipemia effectively, integrates control angina pectoris and hyperlipemia, has breakthrough on therapeutic effect and therapeutic domain.
According to relevant requirements, to meeting coronary heart disease and hyperlipemia diagnostic criteria 100 routine patients with coronary heart disease have carried out the tight observation of the clinical efficacy of this medicine, the January course of treatment.Unify curative effect determinate standard according to the whole nation and judge curative effect, the result shows that tcm syndrome, electrocardiogram myocardial ischemia obvious effective rate are respectively 70%, 36%, and total effective rate is respectively 92%, 73%.Blood fat (TC, TG) obviously reduces, and does not find untoward reaction.
Be several routine model cases below:
Zhang, the man, 65 years old, with the prescription on individual diagnosis that is chief complaint in 8 years of paroxysmal precordial fullness pain.The precordial fullness pain appears in cause fatigue in 8 years, often brings out because of tired later on, continues several minutes at every turn, and the back of having a rest is alleviated, and multiple medicines such as oral administered compound Radix Salviae Miltiorrhizae Tabellae are invalid.Nearly ten days above-mentioned sxs, nervous, breathe hard dark tongue quality, white and thin fur, thready and weak pulse, electrocardio diagram: old inferior myocardial infarction, myocardial ischemia, TG:2.36mmol/L, TC:7.4mmol/L.Diagnosis: coronary heart disease, old myocardial infarction, fatigue angina pectoris; Hyperlipemia.Give each 3 of lipid regulating and meridians activating capsule, day clothes 3 times.After 1 course of treatment, all diseases disappear, and the electrocardiogram ischemic ST-T is clearly better.TG：1.79mmol/L，TC：5.1mmol/L。
Lee, the man, 72 years old, with the prescription on individual diagnosis that was chief complaint in 10 years of paroxysmal chest sense of oppression.Occurred paroxysmal chest sense of oppression before 10 years, often bring out because of tired, continue several minutes to half an hour at every turn, the back of having a rest is alleviated, and multiple medicine such as oral sorbitrate is invalid.The companion is nervous, breathes hard.Electrocardio diagram: extensive antetheca myocardial ischemia, TG:3.22mmol/L, TC:5.9mmol/L.Diagnosis: coronary heart disease, fatigue angina pectoris; Hyperlipemia.Give each 3 of lipid regulating and meridians activating capsule, day clothes 3 times.After 1 course of treatment (30 days), all diseases are clearly better, and the electrocardiogram ischemic ST-T takes a turn for the better.TG：1.85mmol/L，TC?4.7mmol/L。
Yao, woman, 66 years old, prescription on individual diagnosis that is chief complaint in 7 years uncomfortable in chest with paroxysmal, nervous.It is uncomfortable in chest, nervous to occur paroxysmal before 7 years, brings out because of tired, continues several minutes at every turn, and multiple medicines such as oral sorbitrate, metoprolol and Chinese medicine, poor effect are alleviated in the back of having a rest.Health check-up: HR; 72 times/minute, rule is neat, electrocardio diagram: old inferior wall myocardial infarction, antetheca myocardial ischemia, TG1.41mmol/L, TC 8.1mmol/L.Diagnosis: coronary heart disease, old myocardial infarction, fatigue angina pectoris.Hyperlipemia.Give each 3 of lipid regulating and meridians activating capsule, day clothes 3 times.After 1 course of treatment (30 days), all diseases are clearly better, and the electrocardiogram ischemic ST-T takes a turn for the better.TG1.66mmol/L，TC?4.9mmol/L。
Lee, the man, 65 years old, cause fatigue in 8 years occurred behind the breastbone sultry, continued several minutes at every turn, and the back of having a rest is alleviated, and multiple medicines such as oral administered compound Radix Salviae Miltiorrhizae Tabellae are invalid.Above-mentioned symptom increased the weight of in nearly 1 year, repeatedly outbreak.Dark tongue quality, tongue are greasy in vain, thready and weak pulse, electrocardio diagram: antetheca myocardial ischemia, TG:3.64mmol/L, TC:6.8mmol/L.Diagnosis: coronary heart disease, fatigue angina pectoris.Hyperlipemia.Give each 3 of lipid regulating and meridians activating capsule, day clothes 3 times.After 2 courses of treatment, all diseases disappear, and the electrocardiogram ischemic ST-T is clearly better.TG：2.11mmol/L，TC：5.4mmol/L。
Liu, the man, 60 years old, with the suffocating pain over the chest prescription on individual diagnosis that was chief complaint in 5 years.Suffocating pain over the chest occurred before 5 years, often bring out because of tired, continue more than ten minute at every turn, the back of having a rest is alleviated, and multiple medicines such as oral administered compound Radix Salviae Miltiorrhizae Tabellae, sorbitrate are invalid.Dark tongue quality, white and thin fur, weak pulse, electrocardio diagram: extensive antetheca myocardial ischemia, TG:1.69mmol/L, TC6.2mmol/L.Diagnosis: coronary heart disease, angina pectoris, hyperlipemia.Give each 3 of lipid regulating and meridians activating capsule, day clothes 3 times.After 1 course of treatment, all diseases are clearly better, and the electrocardiogram ischemic ST-T takes a turn for the better.TG：1.71mmol/L，TC：4.7mmol/L。
Description of drawings
Fig. 1 is preparation technology's flow chart of the present invention.
The specific embodiment
Embodiment 1
Lipid regulating and meridians activating capsule of the present invention, it is formulated according to following weight percentage ratio by crude drug Radix Ginseng Rubra, Radix Notoginseng, Sanguis Draxonis, Monas cuspurpureus Went, Spina Gleditsiae:
Proportioning: Radix Ginseng Rubra: 25%; Monas cuspurpureus Went: 42%; Spina Gleditsiae: 27%; Radix Notoginseng: 4%; Sanguis Draxonis: 2%;
Preparation method: as shown in Figure 1
The first step, with Radix Ginseng Rubra, Monas cuspurpureus Went, Spina Gleditsiae 60% alcohol reflux, with the ginsenoside Rg
1, ginsenoside Rb
1, ginsenoside Re, total polysaccharides, lovastatin and Spina Gleditsiae saponin extraction ratio and extractum yield be for investigating index, reclaims behind the ethanol Radix Ginseng Rubra, Monas cuspurpureus Went, Spina Gleditsiae alcohol extract to such an extent that extractum is standby;
Second step, Radix Notoginseng, Sanguis Draxonis are beaten powder cross 100 mesh sieves, standby;
The 3rd step, with first step gained extractum, second step gained Radix Notoginseng, the former powder of Sanguis Draxonis mixes the back boiling granulating, crosses 40 mesh sieves, incapsulates and promptly gets patent medicine.
Embodiment 2:
Lipid regulating and meridians activating capsule of the present invention, it is formulated according to following weight percentage ratio by crude drug Radix Ginseng Rubra, Radix Notoginseng, Sanguis Draxonis, Monas cuspurpureus Went, Spina Gleditsiae:
Proportioning: Radix Ginseng Rubra: 30%; Monas cuspurpureus Went: 35%; Spina Gleditsiae: 26%; Radix Notoginseng: 6%; Sanguis Draxonis: 3%;
Preparation method: as shown in Figure 1
The first step, with Radix Ginseng Rubra, Monas cuspurpureus Went, Spina Gleditsiae 60% alcohol reflux, with the ginsenoside Rg
1, ginsenoside Rb
1, ginsenoside Re, total polysaccharides, lovastatin and Spina Gleditsiae saponin extraction ratio and extractum yield be for investigating index, reclaims behind the ethanol Radix Ginseng Rubra, Monas cuspurpureus Went, Spina Gleditsiae alcohol extract to such an extent that extractum is standby;
Second step, Radix Notoginseng, Sanguis Draxonis are beaten powder cross 100 mesh sieves, standby;
The 3rd step, with first step gained extractum, second step gained Radix Notoginseng, the former powder of Sanguis Draxonis mixes the back boiling granulating, crosses 40 mesh sieves, incapsulates and promptly gets patent medicine.
Embodiment 3:
Lipid regulating and meridians activating capsule of the present invention, it is formulated according to following weight percentage ratio by crude drug Radix Ginseng Rubra, Radix Notoginseng, Sanguis Draxonis, Monas cuspurpureus Went, Spina Gleditsiae:
Proportioning: Radix Ginseng Rubra: 27%; Monas cuspurpureus Went: 40.9%; Spina Gleditsiae: 24%; Radix Notoginseng: 5.4%; Sanguis Draxonis: 2.7%.
Preparation method: as shown in Figure 1
The first step, with Radix Ginseng Rubra, Monas cuspurpureus Went, Spina Gleditsiae 60% alcohol reflux, with the ginsenoside Rg
1, ginsenoside Rb
1, ginsenoside Re, total polysaccharides, lovastatin and Spina Gleditsiae saponin extraction ratio and extractum yield be for investigating index, reclaims behind the ethanol Radix Ginseng Rubra, Monas cuspurpureus Went, Spina Gleditsiae alcohol extract to such an extent that extractum is standby;
Second step, Radix Notoginseng, Sanguis Draxonis are beaten powder cross 100 mesh sieves, standby;
The 3rd step, with first step gained extractum, second step gained Radix Notoginseng, the former powder of Sanguis Draxonis mixes the back boiling granulating, crosses 40 mesh sieves, incapsulates and promptly gets patent medicine.
Claims (4)
1. lipid regulating and meridians activating capsule is characterized in that: it is formulated according to following weight percentage ratio by crude drug Radix Ginseng Rubra, Radix Notoginseng, Sanguis Draxonis, Monas cuspurpureus Went, Spina Gleditsiae:
Radix Ginseng Rubra: 25-30%; Monas cuspurpureus Went: 35-42%; Spina Gleditsiae: 24-27%; Radix Notoginseng: 4-6%; Sanguis Draxonis: 2-3%;
Preparation method is:
The first step, with above-mentioned Radix Ginseng Rubra, Monas cuspurpureus Went, Spina Gleditsiae 60% alcohol reflux, reclaim behind the ethanol gained alcohol extract to such an extent that extractum is standby;
Second step, above-mentioned Radix Notoginseng, Sanguis Draxonis are beaten powder cross 100 mesh sieves, standby;
The 3rd step, with first step gained extractum, second step gained Radix Notoginseng, the former powder of Sanguis Draxonis mixes the back boiling granulating, crosses 40 mesh sieves, incapsulates and promptly gets patent medicine.
2. lipid regulating and meridians activating capsule according to claim 1 is characterized in that: the proportioning of described crude drug is: Radix Ginseng Rubra: 25%; Monas cuspurpureus Went: 42%; Spina Gleditsiae: 27%; Radix Notoginseng: 4%; Sanguis Draxonis: 2%.
3. lipid regulating and meridians activating capsule according to claim 1 is characterized in that: the proportioning of described crude drug is: Radix Ginseng Rubra: 30%; Monas cuspurpureus Went: 35%; Spina Gleditsiae: 26%; Radix Notoginseng: 6%; Sanguis Draxonis: 3%.
4. lipid regulating and meridians activating capsule according to claim 1 is characterized in that: the proportioning of described crude drug is: Radix Ginseng Rubra: 27%; Monas cuspurpureus Went: 40.9%; Spina Gleditsiae: 24%; Radix Notoginseng: 5.4%; Sanguis Draxonis: 2.7%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101424243A CN101797330B (en) | 2010-04-09 | 2010-04-09 | Lipid regulating and meridians activating capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101424243A CN101797330B (en) | 2010-04-09 | 2010-04-09 | Lipid regulating and meridians activating capsule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101797330A CN101797330A (en) | 2010-08-11 |
| CN101797330B true CN101797330B (en) | 2011-06-01 |
Family
ID=42593271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101424243A Expired - Fee Related CN101797330B (en) | 2010-04-09 | 2010-04-09 | Lipid regulating and meridians activating capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101797330B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102697982B (en) * | 2012-06-01 | 2014-02-26 | 广州市奥海生物科技有限公司 | Composition having auxiliary blood fat reducing effect and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1375298A (en) * | 2001-01-04 | 2002-10-23 | 黄兆元 | Pain-relieving notoginseng mixture |
| CN1449775A (en) * | 2002-04-09 | 2003-10-22 | 霍照兴 | Medicine composition for preventing and treating thrombosis and relative disease |
| CN1596945A (en) * | 2004-07-21 | 2005-03-23 | 梁辑励 | Chinese herbal plant medicinal oil |
| CN101085134A (en) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | Composition containing dragon blood for treating cardiovascular diseases and preparation |
| CN101513505A (en) * | 2009-03-15 | 2009-08-26 | 威海博力生物工程有限公司 | Capsule used for curing cardiovascular and cerebrovascular diseases |
-
2010
- 2010-04-09 CN CN2010101424243A patent/CN101797330B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1375298A (en) * | 2001-01-04 | 2002-10-23 | 黄兆元 | Pain-relieving notoginseng mixture |
| CN1449775A (en) * | 2002-04-09 | 2003-10-22 | 霍照兴 | Medicine composition for preventing and treating thrombosis and relative disease |
| CN1596945A (en) * | 2004-07-21 | 2005-03-23 | 梁辑励 | Chinese herbal plant medicinal oil |
| CN101085134A (en) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | Composition containing dragon blood for treating cardiovascular diseases and preparation |
| CN101513505A (en) * | 2009-03-15 | 2009-08-26 | 威海博力生物工程有限公司 | Capsule used for curing cardiovascular and cerebrovascular diseases |
Non-Patent Citations (3)
| Title |
|---|
| 张方方等.朱明军教授辨证治疗阵发性房颤经验.《世界中西医结合杂志》.2010,第5卷(第1期),15-16. * |
| 朱明军等.调脂胶囊对动脉粥样硬化家兔血管内皮的保护作用.《中国中医药信息杂志》.2004,第11卷(第11期),982-983. * |
| 谭少猛等.降脂通络法治疗高脂血症78例疗效观察.《现代中西医结合杂志》.2003,第12卷(第19期),2054-2055. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101797330A (en) | 2010-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100382839C (en) | Chinese-medicinal composition for treating coronary heart disease | |
| CN104013849A (en) | Traditional Chinese medicinal composition for treating hypertension and preparation method thereof | |
| CN103948782A (en) | Pharmaceutical composition for treating hyperplasia of mammary glands due to stagnation of liver qi as well as preparation method and application of pharmaceutical composition | |
| CN104906274A (en) | Traditional Chinese medicine for treating coronary heart disease | |
| CN101797330B (en) | Lipid regulating and meridians activating capsule | |
| CN103908490A (en) | Pure plant traditional Chinese medicinal preparation for treating myocardial infarction and cardiovascular diseases and preparation method thereof | |
| CN102579804B (en) | Chinese medicine for treating stenocardia | |
| CN102343049A (en) | Chinese medicinal capsules for treating hypertension due to liver-yang hyperactivity | |
| CN103385963B (en) | Chinese medicine preparation for treating angina pectoris caused by coronary heart disease | |
| CN101991829B (en) | Medicament for treating stomach illness | |
| CN107693621A (en) | Chinese medicine and its preparation for coronary heart disease myocardial infarction treatment | |
| CN102670718A (en) | Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method of same | |
| CN102755444A (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof | |
| CN106822852A (en) | Treat pharmaceutical composition, its preparation technology and the purposes of coronary heart disease | |
| CN106668390B (en) | Traditional Chinese medicine composition for treating hyperthyroidism in early and middle stages | |
| CN101843712A (en) | Chinese medicament for treating angina | |
| CN106728828A (en) | A kind of Chinese medicine preparation and its preparation technology for treating coronary heart disease | |
| CN103655917B (en) | A kind of Chinese medicine for the treatment of cardiovascular and cerebrovascular disease | |
| CN103239620B (en) | Traditional Chinese medicine for treating qi-deficiency heart diseases | |
| CN109954106A (en) | A kind of Chinese medicine preparation and preparation method thereof for treating coronary heart disease | |
| CN102784201B (en) | A kind of caking for the treatment of is without the pasty medicament of head dummy summer boil | |
| CN101991647A (en) | Traditional Chinese medicine for treating diabetic coronary heart diseases | |
| CN101843835B (en) | Chinese medicament for treating coronary diseases | |
| CN101843753A (en) | Chinese medicament for treating angina | |
| CN102091229A (en) | Traditional Chinese medicine for treating diabetic coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110601 Termination date: 20150409 |
|
| EXPY | Termination of patent right or utility model |